Earl R Lewis bought $1,600 of TGEN
director at TECOGEN INC.. 2,000 shares at an average of $0.80, traded Oct 9, 2023, filed Dec 6, 2024.
Score components
- +15RoleDirector
- 0Trade size$2k at market
- -5Relative to holdingsUnder 1% of holdings (0.3%)
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001537435-24-000124, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 9, 2023 | POpen-market purchase Common Stock | +2,000 | $0.80 | $1,600 | 637,000 | Dec 6, 2024 |
Related signals
Other insiders at TECOGEN INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TGENbuy TECOGEN INC. | Stephen Lafaille VP of Business Development | $1,000 400 shares | - | |
| 50Moderate | TGENsell TECOGEN INC. | Stephen Lafaille VP of Business Development | $346k 60,000 shares | -577% | |
| 26Weak | TGENbuy TECOGEN INC. | Earl R Lewis director | $71k 100,000 shares | +16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.